Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
Satellos’ ‘intriguing’ DMD data raise hopes ahead of key readout
Analysts predicted the molecule “could re-imagine the DMD therapeutic landscape” if the biotech replicates the data in children.
Nick Paul Taylor
Jul 8, 2026 9:48am
Big Pharma-backed SonoThera sounds off with $125M series B
Jun 10, 2026 10:48am
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit
Jun 1, 2026 8:31am
Regenxbio reaps pivotal win for Duchenne gene therapy
May 14, 2026 7:25am
Entrada's stock craters as DMD data underperforms expectations
May 7, 2026 9:12am
Regenxbio gene therapy passes interim test as pivotal data loom
Mar 12, 2026 5:49am
